Bio-Techne partners with USP to distribute mAb and AAV standards for biotherapeutic development.

From Nasdaq: 2025-06-24 22:36:00

Bio-Techne Corporation partners with USP to distribute mAb and AAV reference standards for biotherapeutic development, aiming to enhance product quality and safety. The collaboration addresses the growing need for reliable analytics in biosimilar and gene therapy development. The agreement allows Bio-Techne to offer USP’s well-characterized standards alongside its MauriceFlex system, enabling efficient analysis of complex biologics. USP’s Fouad Atouf highlights expanded access to quality solutions, while Bio-Techne’s Will Geist emphasizes a shared commitment to advancing therapeutic development. On Tuesday, TECH closed at $50.00, up 1.42%, with an additional 1.93% gain after hours on the NasdaqGS.



Read more at Nasdaq: Bio-Techne Partners With USP To Distribute MAb And AAV Standards For Biotherapeutic Development